HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs

Why It Matters

Accurate HER2 measurement unlocks ADC therapies for a broader patient pool, directly influencing treatment outcomes and market growth in precision oncology.

Key Takeaways

• AI quantifies HER2 levels beyond visual detection
• Digital pathology enables low/ultra‑low HER2 patient identification
• ADCs like Enhertu target HER2‑low cancers effectively
• Adoption limited by data size, standards, reimbursement
• Cloud imaging centralizes data, supports pathologist collaboration

Pulse Analysis

The convergence of digital pathology and artificial intelligence is reshaping how HER2 expression is assessed in tumor samples. Traditional immunohistochemistry relies on a pathologist’s visual interpretation, which can overlook subtle staining patterns in low‑expressor cancers. AI‑driven image analysis, trained on thousands of annotated slides, quantifies protein levels with reproducible precision, turning HER2 from a binary marker into a nuanced continuum. This granularity enables clinicians to match patients with next‑generation ADCs—such as Enhertu—that are engineered to act on both HER2‑positive and HER2‑low tumors, thereby widening the therapeutic window.

Despite clear clinical benefits, the rollout of computational pathology faces practical obstacles. Whole‑slide images are massive, often 10‑20 times larger than radiology scans, demanding robust storage, high‑speed networking, and scalable cloud infrastructure. Moreover, the field lacks a unified file format; efforts to extend DICOM standards to pathology are still maturing, creating interoperability friction among vendors. Reimbursement models have yet to catch up, leaving many U.S. labs hesitant to invest in the required hardware and software. These barriers contribute to the modest 25 % global adoption rate, with Europe outpacing the United States.

Looking ahead, the integration of AI, cloud‑based imaging, and multi‑ADC companion diagnostics promises a more collaborative oncology ecosystem. Pathologists will increasingly work alongside data scientists to refine predictive algorithms, while oncologists can leverage real‑time analytics to select optimal ADC regimens or combination therapies. Standardization initiatives, such as DICOM for pathology, aim to streamline data exchange, fostering broader clinical trials and accelerating regulatory approvals. As these technologies mature, they are set to become a cornerstone of precision medicine, driving both improved patient outcomes and new revenue streams for biotech firms developing targeted ADC platforms.